Fig. 5
From: TMEM106B aggregation in neurodegenerative diseases: linking genetics to function
Multiple therapeutic strategies targeting TMEM106B for intervention. We proposed that the formation of TMEM106B fibrils may be the key turning point that initiates the downstream pathogenic cascade. Several TMEM106B- or lysosome-based therapeutic approaches have been proposed, including inhibitors of cleavage, improvement of TMEM106B glycosylation, immunotherapy using antibodies against oligomer fibrils, C-terminus aggregation inhibitors and stabilization of lysosome